VALIANTLAB

Valiant Laboratories Share Price

₹82.74 -0.44 (-0.53%)

31 Oct, 2025 3:45 PM (IST)

Start SIP in VALIANTLAB

Start SIP

Performance

  • Low
  • ₹80
  • High
  • ₹84
  • 52 Week Low
  • ₹70
  • 52 Week High
  • ₹121
  • Open Price₹82
  • Previous Close₹83
  • Volume41,892

Investment Returns

  • Over 1 Month + 1.55%
  • Over 3 Month -9.7%
  • Over 6 Month -7.58%
  • Over 1 Year -23.81%

Smart Investing Starts Here Start SIP with Valiant Laboratories for Steady Growth!

Invest Now

Valiant Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 3488.2
  • PEG Ratio
  • 33.9
  • Market Cap Cr
  • 449
  • P/B Ratio
  • 1.4
  • Average True Range
  • 3.58
  • EPS
  • 0.02
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.51
  • RSI
  • 44.44
  • MFI
  • 30.1

Valiant Laboratories Financials

Valiant Laboratories Technicals

EMA & SMA

Current Price
₹82.74
-0.44 (-0.53%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹84.21
  • 50 Day
  • ₹86.10
  • 100 Day
  • ₹89.12
  • 200 Day
  • ₹94.64

Resistance and Support

82.18 Pivot Speed
  • R3 89.33
  • R2 86.76
  • R1 84.75
  • S1 80.17
  • S2 77.60
  • S3 75.59

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Valiant Laboratories Ltd has an operating revenue of Rs. 161.32 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -1% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 45%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 135 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Valiant Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-08-08 Quarterly Results
2025-07-09 Others Inter-alia, to consider 1. Proposal for Raising of Funds by way of issue of securities through further public offer, rights issue, preferential issue or any other method as may be decided. issue of equity shares of Rs. 10/- in the ratio of 1:4 @ premium of Rs. 65/-.
2025-05-20 Audited Results
2025-02-07 Quarterly Results & Others To consider other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:4 @ premium of Rs. 65/-.
2024-11-12 Quarterly Results

Valiant Laboratories F&O

Valiant Laboratories Shareholding Pattern

74.94%
0.02%
18.2%
6.84%

About Valiant Laboratories

  • NSE Symbol
  • VALIANTLAB
  • BSE Symbol
  • 543998
  • Managing Director
  • Mr. Santosh S Vora
  • ISIN
  • INE0JWS01017

Similar Stocks to Valiant Laboratories

Valiant Laboratories FAQs

Valiant Laboratories share price is ₹82 As on 02 November, 2025 | 04:14

The Market Cap of Valiant Laboratories is ₹449.4 Cr As on 02 November, 2025 | 04:14

The P/E ratio of Valiant Laboratories is 3488.2 As on 02 November, 2025 | 04:14

The PB ratio of Valiant Laboratories is 1.4 As on 02 November, 2025 | 04:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23